- Home
- ARWR vs GOF Comparison
ARWR vs GOF Comparison
Compare ARWR & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARWR
- GOF
- Stock Information
- Founded
- ARWR 2003
- GOF 2006
- Country
- ARWR United States
- GOF United States
- Employees
- ARWR N/A
- GOF N/A
- Industry
- ARWR Biotechnology: Pharmaceutical Preparations
- GOF Finance/Investors Services
- Sector
- ARWR Health Care
- GOF Finance
- Exchange
- ARWR Nasdaq
- GOF Nasdaq
- Market Cap
- ARWR 2.5B
- GOF 2.7B
- IPO Year
- ARWR 1993
- GOF N/A
- Fundamental
- Price
- ARWR $31.51
- GOF $14.87
- Analyst Decision
- ARWR Strong Buy
- GOF
- Analyst Count
- ARWR 8
- GOF 0
- Target Price
- ARWR $47.75
- GOF N/A
- AVG Volume (30 Days)
- ARWR 2.8M
- GOF 789.2K
- Earning Date
- ARWR 08-07-2025
- GOF 01-01-0001
- Dividend Yield
- ARWR N/A
- GOF 15.42%
- EPS Growth
- ARWR N/A
- GOF N/A
- EPS
- ARWR N/A
- GOF N/A
- Revenue
- ARWR $572,976,000.00
- GOF N/A
- Revenue This Year
- ARWR $21,619.52
- GOF N/A
- Revenue Next Year
- ARWR N/A
- GOF N/A
- P/E Ratio
- ARWR N/A
- GOF N/A
- Revenue Growth
- ARWR 2816.20
- GOF N/A
- 52 Week Low
- ARWR $9.57
- GOF $10.96
- 52 Week High
- ARWR $31.59
- GOF $16.76
- Technical
- Relative Strength Index (RSI)
- ARWR 75.77
- GOF 42.34
- Support Level
- ARWR $28.12
- GOF $14.84
- Resistance Level
- ARWR $31.13
- GOF $15.11
- Average True Range (ATR)
- ARWR 1.64
- GOF 0.09
- MACD
- ARWR 0.17
- GOF -0.02
- Stochastic Oscillator
- ARWR 98.90
- GOF 9.37
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.